A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (Illuminate 101)
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs IMO 2125 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms illuminate 101
- Sponsors Idera Pharmaceuticals
- 05 Jan 2018 According to an Idera Pharmaceuticals media release, Completed enrollment in first cohort and andvanced enrollment in second cohort.
- 25 Sep 2017 Planned number of patients changed from 40 to 75.
- 12 May 2017 Status changed from not yet recruiting to recruiting.